the efficacy and safety of hydroxyurea therapy vs.switching to ruxolitinib in pv patients
Published 9 years ago • 1.1K plays • Length 6:49Download video MP4
Download video MP3
Similar videos
-
6:49
the efficacy and safety of hydroxyurea therapy vs.switching to ruxolitinib in pv patients
-
1:33
the safety and efficacy of ruxolitinib in polycythemia vera
-
4:17
pv: treatment with ruxolitinib
-
1:09
significance of findings in response trial in polycythemia vera
-
1:40
understanding the role of ruxolitinib in patients with polycythemia vera
-
17:31
how do you treat pv patients that fail hydroxyurea (hu)?
-
0:52
reveal study: long-term analysis of ruxolitinib in patients with polycythemia vera after hydroxyurea
-
1:15
the safety and efficacy of peritransplantation ruxolitinib in patients with mf
-
20:15
hydroxyurea intolerance/resistance in polycythemia vera
-
2:14
long-term 5-year data continues to show response to ruxolitinib in polycythemia vera
-
5:10
ruxolitinib for relapsed/refractory or hydroxyurea-intolerant polycythemia vera patients
-
1:52
safety and efficacy of idasanutlin in pv
-
5:36
case 2: ruxolitinib treatment for polycythemia vera
-
4:07
phase ii study of ruxolitinib: essential thrombocythemia(et) refractory to/intolerant of hydroxyurea
-
8:19
how do i know if hydroxyurea is not right for me?
-
1:27
insights into the reveal trial: the efficacy of ruxolitinib for the treatment of patients with pv
-
0:54
polycythemia vera (pv): is resistance to hydroxyurea prognostic for adverse outcomes?
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
2:09
majic update: promising results for ruxolitinib in pv and et